Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension

Drugs and Aging

Volumn 23, Issue 1, 2006, Pages 39-47

  Fiscella, Richard ^a   Walt, John ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; EYE DROPS; LATANOPROST; TIMOLOL;

ARTICLE; CALCULATION; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; AMIDES; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MODELS, STATISTICAL; OCULAR HYPERTENSION; PROSTAGLANDINS F, SYNTHETIC; TREATMENT OUTCOME;

EID: 33344458363     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200623010-00004     Document Type: Article

References (22)

1. Brandt JD, VanDenburgh AM, Chen K, et al. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Bi matoprost Study Group. Ophthalmology 2001; 108: 1023-31
2. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated IOP: Bimatoprost Study Groups 1 and 2. Surv Ophthalmol 2001; 45 Suppl. 4: S361-8
3. Higginbotham EJ, for the AGN 192024 Study Group 1. 1-year comparison of the new prostamide AGN 192024 with timolol for the management of glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42: S559
4. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995; 102: 1743-52
5. Camras C. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103: 138-47
6. Watson P, Stjernschantz J, for the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-37
7. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension: Bimatoprost Study Group 3. Adv Ther 2001; 18: 110-21
8. Noecker RS, Dirks MS, Choplin NT, et al. A six-month random ized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55-63
9. American Academy of Ophthalmology (AAO). Primary open-angle glaucoma: preferred practice pattern. San Francisco (CA): American Academy of Ophthalmology (AAO), 2000
10. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13
11. Price alert, the official guide to average wholesale pricing. Indianapolis (IN): First DataBank, 2004
12. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term 'cost effective' in medicine. N Engl J Med 1986; 314 (4): 253-6
13. Walt JG, Lee JT. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol 2004; 49 Suppl. 1: S36-44
14. Physicians Fee and Coding Guide. Augusta (GA): MAG Mutual HealthCare Solutions, Inc., 2004
15. Marchetti A, Magar R, An P, et al. Clinical and economic impact of new trends in glaucoma treatment. MedGenMed 2001; 3 (3): 6
16. Kobelt G. Health economics: an introduction to economic evaluation. 2nd ed. London: Office of Health Economics, 2002
17. Verispan. The true measure of healthcare [online]. Available from URL: http://www.verispan.com [Accessed 2006 Jan 9]
18. Dix Smith M, editor. Health care cost, quality, and outcomes: ISPOR book of terms. Lawrenceville (NJ): International Society for Pharmacoeconomic and Outcomes Research, 2005: 74-6
19. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications, 2004. J Manag Care Pharmacy. In press
20. Day DG, Schacknow PN, Sharpe ED, et al. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocular Pharmacol Ther 2004; 20: 383-92
21. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004; 137: S13-6
22. Fiscella RG. Persistency with glaucoma medication. Am J Ophthalmol 2004; 138: 1093-4